glp-1 and liver Therapeutic Mechanisms Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Disease Glucagon-like peptide 1 decreases lipotoxicity

Follow-up Information on follow-up was obtained from healthcare professionals and patients in similar proportions for both the GLP1-RA and the reference groups with diabetes and who were overweight/obese: healthcare professionals 10% vs 9% and 6% and patients 90% vs 91% and 94%, respectively

Economic modeling studies suggest that effective weight loss medications can reduce overall healthcare costs through decreased diabetes, cardiovascular disease, and other obesity-related complications

If you suspect you are experiencing side effects from your GLP-1 medication, you can report these through the MHRA Yellow Card scheme (www.mhra.gov.uk/yellowcard)

Streamlining insurance approvals is one way to lower costs

8 Greater weight loss was associated with a higher incidence of MASH resolution without worsening of fibrosis, but this association with weight loss was less evident for reduction in fibrosis without worsening of MASH